KBC Group
PRAX icon

KBC Group’s Praxis Precision Medicines PRAX Stock Holding History

KBC Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$230K Buy
715
+39
+6% +$12.1K ﹤0.01% 932
2025
Q4 		$199K Buy
+676
New +$126K ﹤0.01% 921

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

KBC Group's PRAX Position: Q1 2026 in Review

KBC Group increased its Praxis Precision Medicines (PRAX) stake by 5.8% in Q1 2026, buying an estimated $12.1K and bringing the position to 715 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

KBC Group first reported a position in PRAX in Q4 2025 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • KBC Group held 715 shares of Praxis Precision Medicines worth $230K as of Q1 2026.
  • KBC Group bought 39 Praxis Precision Medicines shares in Q1 2026, an estimated $12.1K.
  • Praxis Precision Medicines made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #932 holding.
  • KBC Group first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.